Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 2/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CDC25A | P30304 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26544451 | 0.84 | NR1H4 (0.50) | CYP1A2ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL9691004 | 0.84 | CYP1A2 (0.47) | CYP1A2RXRBRXRAALDH1A1NPC1 | |
| SCHEMBL13206915 | 0.84 | RAB9A (0.42) | CYP1A2ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL709947 | 0.83 | HSD17B10 (0.47) | CYP1A2ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL15154757 | 0.82 | NPC1 (0.58) | CYP1A2RXRBRXRAALDH1A1NPC1 | |
| SCHEMBL28156075 | 0.82 | RAB9A (0.51) | ALDH1A1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL27762519 | 0.81 | SMN1; SMN2 (0.47) | ALDH1A1KMT2AMEN1LMNAMAPT | |
| Hydrochloric Acid SCHEMBL2176205 | 0.81 | NPC1 (0.56) | CYP1A2RXRBRXRAALDH1A1NPC1 | |
| SCHEMBL377804 | 0.81 | MYC (0.58) | CYP1A2ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL29400790 | 0.80 | KDM4C (0.50) | ALDH1A1KMT2AMEN1MAPTAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858919-B2 | HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20220033388-A1 | HDAC1,2 Inhibitors | REGENACY PHARMACEUTICALS, LLC | 2022-02-03 | — | — | US | disclosed |
| EP-3856174-A1 | HDAC1,2 INHIBITORS | Regenacy Pharmaceuticals, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020068950-A1 | HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC (US) | 2020-04-02 | — | — | WO | disclosed |
| EP-2804849-B1 | AMINO PHOTO-REACTIVE BINDER | ALLNEX Belgium SA (BE) | 2018-06-27 | — | — | EP | disclosed |
| US-10005717-B2 | Photo-reactive binder | ALLNEX BELGIUM S.A. (BE) | 2018-06-26 | — | — | US | disclosed |
| US-10000446-B2 | Amino photo-reactive binder | ALLNEX BELGIUM S.A. (BE) | 2018-06-19 | — | — | US | disclosed |
| EP-2804914-B1 | PHOTO-REACTIVE BINDER | ALLNEX Belgium SA (BE) | 2016-07-20 | — | — | EP | disclosed |
| EP-2804849-A1 | AMINO PHOTO-REACTIVE BINDER | Allnex Belgium, S.A. (BE) | 2014-11-26 | — | — | EP | disclosed |
| US-20140335327-A1 | AMINO PHOTO-REACTIVE BINDER | ALLNEX BELGIUM S.A. (BE) | 2014-11-13 | — | — | US | disclosed |
| WO-2002064578-A1 | BENZO THIADIAZINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| US-20020049243-A1 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. | 2002-04-25 | — | — | US | disclosed |
| EP-1062209-A4 | METABOLICALLY INERT ANTI-INFLAMMATORY AND ANTI-TUMOR ANTIFOLATES | NAIR MADHAVAN G (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2002006222-A1 | PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | disclosed |
| WO-2001079180-A2 | 5-SUBSTITUTED TETRALONES AS INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2001-10-25 | — | — | WO | disclosed |
| US-6291673-B1 | Folic acid derivatives | PURDUE RESEARCH FOUNDATION | 2001-09-18 | — | — | US | disclosed |
| EP-1062209-A1 | METABOLICALLY INERT ANTI-INFLAMMATORY AND ANTI-TUMOR ANTIFOLATES | NAIR, Madhavan G. (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999036409-A1 | METABOLICALLY INERT ANTI-INFLAMMATORY AND ANTI-TUMOR ANTIFOLATES | NAIR MADHAVAN G (US) | 1999-07-22 | — | — | WO | disclosed |
| US-5912251-A | ENZYME INHIBITORS | CHELSEA THERAPEUTICS, INC. | 1999-06-15 | — | — | US | disclosed |
| WO-1999020626-A1 | FOLIC ACID DERIVATIVES | PURDUE RESEARCH FOUNDATION (US) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335327-A1 | AMINO PHOTO-REACTIVE BINDER | ADGRE5, METTL14, CD79B | CYP1A2 2455/4885RXRB 3482/4885RXRA 3540/4885 |
| US-10000446-B2 | Amino photo-reactive binder | ADGRE5, GP6, CD79B | CYP1A2 2430/4885RXRB 3533/4885RXRA 3534/4885 |
| US-10005717-B2 | Photo-reactive binder | CD79B, ADGRE5, GP6 | CYP1A2 2129/4885RXRB 2085/4885RXRA 2320/4885 |
| US-11858919-B2 | HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | CYP1A2 3185/4885RXRB 2455/4885RXRA 2582/4885 |
| US-20220033388-A1 | HDAC1,2 Inhibitors | HDAC1, HDAC2, HDAC11 | CYP1A2 3185/4885RXRB 2455/4885RXRA 2582/4885 |
| US-20020049243-A1 | Pyrrolidine derivatives | PREP, PEPD, DNPEP | CYP1A2 1016/4885RXRB 4084/4885RXRA 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.